Genetic Signatures (GSS) Stock Overview
Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
GSS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Genetic Signatures Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.30 |
| 52 Week High | AU$0.73 |
| 52 Week Low | AU$0.21 |
| Beta | 0.55 |
| 1 Month Change | 22.00% |
| 3 Month Change | -10.29% |
| 1 Year Change | -57.34% |
| 3 Year Change | -59.87% |
| 5 Year Change | -84.60% |
| Change since IPO | -37.11% |
Recent News & Updates
Recent updates
We Think Genetic Signatures (ASX:GSS) Can Afford To Drive Business Growth
Aug 25
We Think Genetic Signatures (ASX:GSS) Can Afford To Drive Business Growth
May 08Genetic Signatures Limited (ASX:GSS) Might Not Be As Mispriced As It Looks After Plunging 30%
Apr 11Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult
Jun 14After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar
Mar 08A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)
Nov 14Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected
Oct 10One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates
Jun 29Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Feb 28AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results
Feb 25What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?
Feb 07
What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?
Jan 17Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth
Dec 27Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business
Dec 06Shareholder Returns
| GSS | AU Life Sciences | AU Market | |
|---|---|---|---|
| 7D | -16.4% | -9.2% | -1.5% |
| 1Y | -57.3% | -42.3% | 9.4% |
Return vs Industry: GSS underperformed the Australian Life Sciences industry which returned -36.8% over the past year.
Return vs Market: GSS underperformed the Australian Market which returned 8.9% over the past year.
Price Volatility
| GSS volatility | |
|---|---|
| GSS Average Weekly Movement | 19.1% |
| Life Sciences Industry Average Movement | 10.6% |
| Market Average Movement | 9.5% |
| 10% most volatile stocks in AU Market | 20.2% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: GSS's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: GSS's weekly volatility has increased from 14% to 19% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Ali Rossiter | www.geneticsignatures.com |
Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. It offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, extended respiratory, atypical respiratory, Measles, Mumps, and Rubella detection kits under the EasyScreen name. The company was incorporated in 2001 and is headquartered in Newtown, Australia.
Genetic Signatures Limited Fundamentals Summary
| GSS fundamental statistics | |
|---|---|
| Market cap | AU$69.28m |
| Earnings (TTM) | -AU$20.10m |
| Revenue (TTM) | AU$19.75m |
Is GSS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GSS income statement (TTM) | |
|---|---|
| Revenue | AU$19.75m |
| Cost of Revenue | AU$9.25m |
| Gross Profit | AU$10.51m |
| Other Expenses | AU$30.61m |
| Earnings | -AU$20.10m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.089 |
| Gross Margin | 53.19% |
| Net Profit Margin | -101.78% |
| Debt/Equity Ratio | 0% |
How did GSS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/31 00:08 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genetic Signatures Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anubhav Saxena | Bell Potter |
| Thomas Wakim | Bell Potter |
| Dennis Hulme | Taylor Collison Limited |